Valneva

Pharmaceutical company developing prophylactic vaccines to treat infectious diseases

Company website

Ticker

VALN.NASDAQ

Market

Foundation year

2013

Close date

7/1/2021

IPO date

5/5/2021

Placement price

$26.41

Profitability

1.86%

About

Total Funding

$577.1M

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19.

Number of employees

500-1000

Headquarters

Saint-herblain, Pays de la Loire, France